Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      hAMSCs regulate EMT in the progression of experimental pulmonary fibrosis through delivering miR-181a-5p targeting TGFBR1

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Pulmonary fibrosis (PF) is a common and multidimensional devastating interstitial lung disease. The development of novel and more effective interventions for PF is an urgent clinical need. A previous study has found that miR-181a-5p plays an important role in the development of PF, and human amniotic mesenchymal stem cells (hAMSCs) exert potent therapeutic potential on PF. However, whether hAMSCs act on PF by delivering miR-181a-5p and its detailed mechanism still remain unknown. Thus, this study was designed to investigate the underlying possible mechanism of hAMSCs on PF in bleomycin (BLM)-induced mouse PF model, and a co-culture system of hAMSCs and A549 cells epithelial mesenchymal transition (EMT) model, focusing on its effects on collagen deposition, EMT, and epithelial cell cycle regulation.

          Methods

          hAMSCs with different miR-181a-5p expression levels were constructed. BLM (4 mg/kg) was used to create a PF model, while TGF-β1 was used to induce A549 cells to construct an EMT model. Furthermore, the effects of different miR-181a-5p expression in hAMSCs on collagen deposition and EMT during lung fibrosis were assessed in vivo and in vitro.

          Results

          We found that hAMSCs exerted anti-fibrotic effect in BLM-induced mouse PF model. Moreover, hAMSCs also exerted protective effect on TGFβ1-induced A549 cell EMT model. Furthermore, hAMSCs ameliorated PF by promoting epithelial cell proliferation, reducing epithelial cell apoptosis, and attenuating EMT of epithelial cells through paracrine effects. hAMSCs regulated EMT in PF through delivering miR-181a-5p targeting TGFBR1.

          Conclusions

          Our findings reveal for the first time that hAMSCs inhibit PF by promoting epithelial cell proliferation, reducing epithelial cell apoptosis, and attenuating EMT. Mechanistically, the therapeutic effect of hMASCs on PF is achieved through delivering miR-181a-5p targeting TGFBR1.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13287-024-04095-3.

          Related collections

          Most cited references101

          • Record: found
          • Abstract: found
          • Article: not found

          An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

          American Journal of Respiratory and Critical Care Medicine, 183(6), 788-824
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis

            Human lung single-cell atlas reveals the complexity and diversity of aberrant cellular populations in pulmonary fibrosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases

              Mesenchymal stem cells (MSCs; also referred to as mesenchymal stromal cells) have attracted much attention for their ability to regulate inflammatory processes. Their therapeutic potential is currently being investigated in various degenerative and inflammatory disorders such as Crohn's disease, graft-versus-host disease, diabetic nephropathy and organ fibrosis. The mechanisms by which MSCs exert their therapeutic effects are multifaceted, but in general, these cells are thought to enable damaged tissues to form a balanced inflammatory and regenerative microenvironment in the presence of vigorous inflammation. Studies over the past few years have demonstrated that when exposed to an inflammatory environment, MSCs can orchestrate local and systemic innate and adaptive immune responses through the release of various mediators, including immunosuppressive molecules, growth factors, exosomes, chemokines, complement components and various metabolites. Interestingly, even nonviable MSCs can exert beneficial effects, with apoptotic MSCs showing immunosuppressive functions in vivo. Because the immunomodulatory capabilities of MSCs are not constitutive but rather are licensed by inflammatory cytokines, the net outcomes of MSC activation might vary depending on the levels and the types of inflammation within the residing tissues. Here, we review current understanding of the immunomodulatory mechanisms of MSCs and the issues related to their therapeutic applications.
                Bookmark

                Author and article information

                Contributors
                hzx@gmc.edu.cn
                Journal
                Stem Cell Res Ther
                Stem Cell Res Ther
                Stem Cell Research & Therapy
                BioMed Central (London )
                1757-6512
                5 January 2025
                5 January 2025
                2025
                : 16
                : 2
                Affiliations
                [1 ]Key Laboratory of Cell Engineering of Guizhou Province, Affiliated Hospital of Zunyi Medical University, ( https://ror.org/00g5b0g93) Zunyi, 563000 Guizhou China
                [2 ]Collaborative Innovation Center of Chinese Ministry of Education, Zunyi Medical University, ( https://ror.org/00g5b0g93) Zunyi, 563003 Guizhou China
                [3 ]Department of Prevention Healthcare, Southwest Hospital, First Affiliated Hospital of the Army Medical University, ( https://ror.org/02jn36537) Chongqing, 400038 China
                [4 ]Department of Cardiothoracic Surgery, Liuzhou People’s Hospital, ( https://ror.org/01y8cpr39) Liuzhou, 545001 Guangxi China
                [5 ]Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi, 563000 Guizhou China
                [6 ]Department of Pediatrics, Affiliated Hospital of Zunyi Medical University, ( https://ror.org/00g5b0g93) Zunyi, 563000 Guizhou China
                [7 ]Center of Tissue Engineering and Stem Cell Research, Guizhou Medical University, ( https://ror.org/035y7a716) Guiyang, 550025 Guizhou China
                [8 ]Department of Pediatric Hematology, The Affiliated Hospital of Guizhou Medical University, ( https://ror.org/02kstas42) Guiyang, 550025 Guizhou China
                Article
                4095
                10.1186/s13287-024-04095-3
                11702096
                39757225
                2db69cb6-a26a-42fe-b457-2e28ccb7e018
                © The Author(s) 2025

                Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

                History
                : 11 September 2024
                : 4 December 2024
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100014718, Innovative Research Group Project of the National Natural Science Foundation of China;
                Award ID: No : 32270848
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100018555, Science and Technology Program of Guizhou Province;
                Award ID: Qian Ke He【2020】4Y192
                Award ID: No. QKH-JC-ZK[2023]YB586
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100022424, Ministry of Scientific and Technological Development, Higher Education and Information Society;
                Award ID: Grant Number:2020-39
                Award Recipient :
                Funded by: Guizhou Province High Level Innovative Talent Training Program
                Categories
                Research
                Custom metadata
                © BioMed Central Ltd., part of Springer Nature 2025

                Molecular medicine
                amniotic membrane mesenchymal stem cells,hamscs,pulmonary fibrosis,epithelial mesenchymal transition,mir-181a-5p,tgfbr1

                Comments

                Comment on this article